|
NFXL1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.46549439250521E-14 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.7545964681176E-12 |
| Normal-vs-Stage2 |
8.16569034611803E-13 |
| Normal-vs-Stage3 |
1.626032641866E-12 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
5.702600E-01 |
| Stage1-vs-Stage3 |
5.439700E-02 |
| Stage1-vs-Stage4 |
1.761960E-03 |
| Stage2-vs-Stage3 |
4.180000E-01 |
| Stage2-vs-Stage4 |
7.638000E-02 |
| Stage3-vs-Stage4 |
2.532000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.63025148935958E-12 |
| Normal-vs-AfricanAmerican |
7.06220000257218E-08 |
| Normal-vs-Asian |
1.82454051866898E-12 |
| Caucasian-vs-AfricanAmerican |
6.243800E-01 |
| Caucasian-vs-Asian |
8.571200E-01 |
| AfricanAmerican-vs-Asian |
7.605000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.63946634046397E-12 |
| Normal-vs-Female |
1.64157576421076E-12 |
| Male-vs-Female |
8.103000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.73665592596262E-14 |
| Normal-vs-Age(41-60Yrs) |
7.99360577730113E-15 |
| Normal-vs-Age(61-80Yrs) |
9.32587340685131E-15 |
| Normal-vs-Age(81-100Yrs) |
1.800630E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.918800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.766000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.603400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.757200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.679800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.179400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.757600E-03 |
| Classical-VS-Follicular |
5.396000E-01 |
| Classical-VS-Other |
5.124000E-01 |
| Classical-VS-Normal |
2.30149233004795E-13 |
| Tall-VS-Follicular |
1.107530E-02 |
| Tall-VS-Other |
2.052600E-01 |
| Tall-VS-Normal |
1.62569957495862E-12 |
| Follicular-VS-Other |
5.761800E-01 |
| Follicular-VS-Normal |
4.53226345342728E-12 |
| Other-VS-Normal |
8.799800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.65290003906193E-12 |
| Normal-vs-N1 |
1.6269208202857E-12 |
| N0-vs-N1 |
1.366030E-01 |
|
|
